John W. Childs - Oct 3, 2022 Form 4/A - Amendment Insider Report for Biohaven Ltd. (BHVN)

Role: Director
Signature: /s/ George Clark, Attorney-in-Fact
Stock symbol: BHVN
Transactions as of: Oct 3, 2022
Transactions value $: $0
Form type: 4/A - Amendment
Date filed: 10/5/2022, 09:35 PM
Date Of Original Report: Oct 5, 2022
Previous filing: Sep 30, 2022
Next filing: Oct 5, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BHVN	Common Shares	Other	$0	+1.51M	+32809.11%	$0.00	1.52M	Oct 3, 2022	Direct	F1, F2
transaction	BHVN	Common Shares	Other	$0	+5K		$0.00	5K	Oct 3, 2022	By John W Childs 2013 Revocable Trust	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer").
F2	This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Shares acquired were indirectly held by the Reporting Person in the John W. Childs 2013 Revocable Trust. There were no other changes made to the information in the Original Filing.

Content

Represents common shares of the Issuer ("Common Shares") acquired by the Reporting Person in a pro rata distribution by Biohaven Pharmaceutical Holding Company Ltd.. ("RemainCo") to holders of its common shares (the "Distribution") pursuant to the Separation and Distribution Agreement (the "Separation Agreement"), dated as of May 9, 2022, by and among RemainCo, the Issuer, and Pfizer Inc. ("Pfizer").

This amendment is being filed to correct the form of ownership reported in the Form 4 filed on October 5, 2022 (the "Original Form 4"). The Original Form 4 inadvertently incorrectly reported that all Common Shares acquired were directly held by the Reporting Person; however, as reflected in this amendment, a portion of the Shares acquired were indirectly held by the Reporting Person in the John W. Childs 2013 Revocable Trust. There were no other changes made to the information in the Original Filing.